MGLL and Parkinson disease: It has been recently reported that in the animal models of Parkinson and Alzheimer’s disease, the therapeutic effect of MAGL inhibitors is dependent on the reduced production of AA and prostaglandins rather than on the elevated cannabinoid signaling from high brain levels of 2-AG [35–37].